

**Notice Information: - 3rd Party Publications
21 December 2012**

Part 1. Product Information

- a) Title:
- b) Product Name/Type:
- c) Active Substance:

Part 2. Problem/Issue

- a) Problem/Issue:

Part 3. Action to be taken

a) Action to be taken:

Pending the outcome of this review (expected in January 2013), the EMA recommends that no new patients should be started on treatment with these medicines. Patients currently using Tredaptive, Pelzont or Trevaclyn should not stop their treatment. Patients who have any questions should speak to their doctor at their next appointment.

Healthcare professionals in the European Union (EU) will receive a letter in the next few days outlining the updated information on the use of these medicines.

For full EMA statement please refer to link below.

European Medicines Agency - press release

Tredaptive (nicotinic acid/laropiprant) - Letter to Healthcare Professionals

Irish Medicines Board communication on PRAC recommendation on Tredaptive

Part 4. Keywords

a) Keywords:

Tredaptive Pelzont Trevaclyn